|[November 30, 2012]
Xcovery's Dual VEGF/PDGFR Inhibitor, X-82 Named to 2012 Top Projects to Watch Hot Space List
WEST PALM BEACH, Fla. & BOSTON --(Business Wire)--
lead product X-82, a dual VEGFR/PDGFR inhibitor being studied for both
ophthalmology and cancer, has been named to Elsevier Business
Intelligence's (EBI) prestigious 2012 Top Projects to Watch list in the
Hot Space category for ophthalmology. Xcovery
Vision, a subsidiary of Xcovery Holdings, and Tyrogenex, Inc., are
privately held companies focused on developing the next generation of
eye therapeutics and targeted therapeutics for cancer, respectively.
In related news, Xcovery Vision dosed its first patient in its Phase
I/II clinical study to evaluate the safety and preliminary biologic
activity/efficacy of X-82 in patients with wet age-related macular
degeneration (AMD (News - Alert)). Nauman Chaudhry, MD, of New England Retina
Associates in New London, Conn., is the principal investigator.
"We are honored to be named to this exclusive list of therapeutic
advances as we begin our clinical study for the ophthalmology
indication," said Sheridan G. Snyder, chairman and chief executive
officer of Xcovery. "Xcovery is making tremendous progress in the
advancement of X-82 for ophthalmology and cancer."
Companies and the products that make the Top Projects to Watch are
hand-picked by a panel of independent experts who screen hundreds of
compounds and weigh their potential as future products.
The orally administered X-82 targets basic biologic processes, such as
inflammation and neovascularization, which are relevant to ophthalmic
indications, such as AMD, diabetic retinopathy, dry eye syndrome, ocular
allergy, uveitis and postoperative inflammation. In cancer indications,
VEGFR tyrosine kinase inhibitors have characteristically demonstrated
benefit in a variety of cancers, though it has been well ocumented that
the dosage and use of this class in combination with other therapies has
been limited by side effects. At the American Society of Clinical
Oncology (ASCO) meeting in June, Xcovery presented preliminary data that
showed X-82 was well tolerated, did not exhibit any dose-limiting
toxicity and demonstrated preliminary signs of anti-tumor activity,
including a complete response in a patient with pancreatic cancer and
stable disease in five other cancer patients.
"We are encouraged by our preliminary results and this recognition from
EBI," said Dr. Liang, who is available for one-on-one partnership
meetings at the Therapeutic Area Partnerships Conference. "The data
support our hypothesis that X-82 will be a differentiated and ideal
product candidate for oral treatment of AMD and combination therapy for
About Xcovery Vision's Phase I/II Clinical Study
The goal of
the Phase I/II study is to assess the preliminary safety of X-82 over a
range of doses and evidence of biologic activity as measured by
improvement in vision and reduction of subretinal fluid. Patients will
also be provided access to the standard-of-care anti-VEGF therapy if
they meet specific treatment criteria. Enrollment is planned to begin in
October 2012, and the study is expected to last about 12 months.
AMD is the leading cause of blindness for people
over the age of 50 in the United States and Europe. There are two forms
of the disease, namely "dry" and "wet" AMD. The "wet" form is
characterized by the growth of new blood vessels into the central region
of the retina. These new vessels cause severe visual loss due to retinal
damage caused by subsequent leakage and scar formation. Anti-VEGF
therapies and photodynamic therapies have been approved for "wet" AMD.
"Dry" AMD accounts for up to 90 percent of all cases of AMD. There is no
approved therapy for "dry" AMD, which afflicts 8 million patients in the
United States and an additional 8 million in Europe. Visual loss in
"dry" AMD is typically not as severe as "wet" AMD, however, over time,
dry AMD can progress to the wet form of the disease.
About Xcovery Holdings
Xcovery is a holding company focused
on the development of next-generation targeted therapeutics for cancer
and ophthalmology funded by Biocatalyst International, a closely held
early-stage venture fund. Xcovery Holdings has developed a broad
portfolio of small molecule kinase inhibitors and has several active
collaborations with leading academic and clinical centers to further
validate the use of these candidates in a number of disease indications
and in various combinations.
About Xcovery Vision
Xcovery Vision is an
ophthalmology-focused subsidiary of Xcovery Holdings, a clinical-stage
company developing novel therapies for cancer and inflammatory diseases.
Xcovery Vision's goal is to develop innovative therapies to address
unmet healthcare needs and improve the standard of care in the field of
ophthalmology. Xcovery Vision is developing a comprehensive pipeline of
ophthalmology therapies that target basic mechanisms of eye disease,
including angiogenesis, fibrosis and inflammation.
Tyrogenex is affiliated with Xcovery
Holdings. It was founded by Sherry Snyder through Biocatalyst
International in partnership with Dr. Chris Liang. Through this
partnership, Tyrogenex has developed a novel, patented cancer
therapeutic, X-82. The compound, a dual VEGFR/PDGFR inhibitor, is being
studies in a clinical trial for the treatment of advanced solid tumors.
About Windhover Conferences
Windhover Conferences is an
Elsevier Business Intelligence company, the leading provider of business
intelligence and analysis to senior executives in the medical device,
pharmaceutical, and biotechnology industries. Through a range of
products including publications, conferences, e-learning, databases and
reports, Elsevier Business Intelligence places biopharma and medical
device professionals, and those who focus on these industries, at the
forefront of knowledge, by providing the perfect combination of news and
information together with penetrating insight and analysis. Its leading
publications include PharmAsia News, IN VIVO and "The Pink Sheet."
[ InfoTech Spotlight's Homepage ]